Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He's not gonna be happy.... I believe he's a penny trader... Imho.
We're gonna be happy!!
I believe a partner announcement is underway... Imho.
I hope history doesn't repeat itself today.... If it does... That would mean down.
The Memorial Sloan Kettering (MSK) Cancer Center in New York City is the top-ranked cancer hospital in the United States for 2014/15, according to the annual rankings from U.S. News & World Report.
MSK is the first-place finisher in cancer care after 7 straight years of being runner-up to the University of Texas M.D. Anderson Cancer Center in Houston.
However, it is not exactly a big drop for M.D. Anderson. MSK scored 100 out of a possible 100, and M.D. Anderson scored 99.9.
Still, first place is first place for MSK.
"We are delighted and honored to once again be a top hospital for cancer," said MSK president and CEO Craig Thompson, MD, in a press statement.
MSK has held either the first or second spot every year since the first list was issued 25 years ago.
"They ended up at number 1 by the thinnest of margins," Avery Comarow, the health rankings editor at U.S. News & World Report, told Medscape Medical News in an interview.
But at least it was a fair fight this year.
The top ranking assigned to M.D. Anderson in 2013 was aided by mortality/survival data that were, in the words of Comarow, "massively" in error," as reported last year by Medscape Medical News. The data mix-up improved the Texas center's score over a number of years.
"This is the first year that the survival data have been free of the errors of the past," said Comarow.
For their part, M.D. Anderson was sporting in relinquishing the top spot.
"We...congratulate Memorial Sloan Kettering Cancer Center on their No. 1 ranking this year," reads a statement from the Texas center.
Totally agree Dave... If we're still under a buck fifty by tomorrow's close, I can turn it back on and pick some up Tuesday morning.. :)
Good luck!
Same as Chris!! Thanks for all you do.
It is... Cats out of the bag Sunday. Imho.
I shut off my Sharebuilder account a few weeks ago... Just that feeling I'll never be able to pick up more shares under a buck fifty... We shall see.
Something smells!! Is this a pull down before we get some good news?
Problem is, GALE keeps going up... PPHM is going down!!
I did say after the first Tuesday in May, it would probably be the last time I'll be able to pick up shares under $1.50 thru my Sharebuilder account... Hope I'm right... And I truly hope I'm way off on the 2015&2016 pps guessing game!
I'm in too... 12/31/15 = $1.48 -- 6/30/16 = $1.75
If Ph3 is a bust... They restructure, in the end they have Avid and we have nothing.
Same here on May 7...
History of Changes and the ClinicalTrials.gov Archive Site
Information in a ClinicalTrials.gov record can be modified at any time by the data provider.
The display at ClinicalTrials.gov shows the most recent version for each data element.
The date first received and the date last updated are listed at the top of each record.
The full history of changes since the record was first received is available in the
archival version of the record on the ClinicalTrials.gov Archive Site.
Current Study:
ClinicalTrials.gov Identifier: NCT01634685
Study Title: A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
First Received: June 28, 2012
Last Updated: May 7, 2015
What was changed or updated on May 5th??
History of Changes and the ClinicalTrials.gov Archive Site
Information in a ClinicalTrials.gov record can be modified at any time by the data provider.
The display at ClinicalTrials.gov shows the most recent version for each data element.
The date first received and the date last updated are listed at the top of each record.
The full history of changes since the record was first received is available in the
archival version of the record on the ClinicalTrials.gov Archive Site.
Current Study:
ClinicalTrials.gov Identifier: NCT01984255
Study Title: A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
First Received: October 29, 2013
Last Updated: May 5, 2015
I sure did... In @ $1.30... Isn't it about that time to start moving up into the $1.40's again?
Up and down and around she goes... Where I get in this morning Nobody knows....
Lol is right!! My guess like I said before... Next Tuesday will be my last buying opportunity under $1.50... If not... I'll do it again next month.
I'm ready to rock & roll more shares next week!!.... I for one, do wonder if this stuff works... Only some know for sure!! I wonder who? :)
Dear James,
The more you add to your Capital One® ShareBuilder® account, the more power you'll have to seize an opportunity. Whether you deposit cash or transfer assets, you've already got these advantages:.... Steve, I'm placing all my chips on Bavi... Just sayen.
Buy, buy, buy!! I'm doing more side jobs than ever!!... This Tuesday will be a great buy I'm hoping..
Don't you have to wait for Ph3 to be over, successful and approved before you start making profits?...
You need to sit back (patients) and wait a little longer... Another year/half... Me? I buy every month.
Itsabout.. You think BP can take a drug thru all the phases much quicker than SP companies?...
I totally agree..., Cotara can sit on the shelf... Let Bavi hit a home run... It better... If not, we had Oncolym, Cotara and Bavi that hit a brick wall..
Cotara was approved for Ph3... They never started it... End of story.
Nice post Couch... Reminds the negative Nancy's what's really going on.
That's great Couch.... I can't wait till next Tuesday... Should be another great buy unless we get some good news between now and then.
This "if true" will be a blockbuster drug!! I just don't understand why the market doesn't see this.... It's like to good to be true... I still believe.
Hopefully we find out one day.... If not, oh well.... We move on.... With the carboat of course.
What do you mean planned wook?? I'm really starting to think like CB... Was it just a mistake??.... Wonder if we'll ever know....
So, your saying it was a simple mistake what happen? Or did JB do it on purpose?
I was referring too... I believe the pps will be higher than a $1.50 after this last buying opportunity.. Meaning, after the 1st Tuesday in May we start heading over a buck fiddy, I'll turn my investment plan off... If we continue under a buck fiddy, I'll leave it on.
I'm sitting in the same exact spot were I was on that dreaded Monday morning, when I got on my phone and watched pphm go from $5+ to .80 in minutes... Talk about a sick feeling... Oh the memory hits hard when I'm here.
The first Tuesday of May will probably be my last buy under $1.50... Just sayin... Fortunately, I have to turn off my monthly investment plan... Oh well, I got plenty of shares!!.. Finally!
Roth Capital affirmed Peregrine Pharma (Nasdaq: PPHM) at Buy with a price target of $5 after the company announced the presentation of data from clinical translational studies of the company's phosphatidylserine (PS)-targeting immunotherapy bavituximab. Peregrine said that initial data from a pilot study of clinical translational ex vivo cultures show that bavituximab, both alone and with docetaxel, elicits evidence of a tumor-specific immune response in patients with human adenocarcinoma of the lung and that bavituximab exhibits an impact on tumors with negative PD-L1 expression.
Analyst Joseph Pantginis commented, "We generally do not write on preclinical data, however we believe these data continue to represent important incremental steps in defining bavituximab's immunotherapy mechanism of action. In the lung model, immune response to treatment correlates with negative PD-L1 expression and low PD-1 expression on CD8+ tumor cells, which could represent a prognostic biomarker. We believe these data represent the closest ex-vivo model of the patient population being assessed in the ongoing Phase III SUNRISE study in second-line NSCLC. Nilogen’s drug discovery platform is described in the figure below. Over the next 12-months we expect to see an increase in visibility on the shares based on 1) completion of enrollment into the Phase III SUNRISE study, 2) incremental data updates from earlier clinical studies, and 3) increasing visibility for bavituximab's mechanism of action within the immuno-oncology landscape. The ~600 patient SUNRISE study in 2nd-line NSCLC is expected to complete enrollment by the end of 2015. By the end of April, we also expect final data from the Phase I IST in HER-2 negative metastatic breast cancer."
I'm going with, something could happen between now and the end of 2016... That's a fact... Either something good or something bad... Take your gamble.
I can almost be certain that soon is gonna be a year and a half from now... Not sure what's gonna happen in between... So, "soon" could mean anytime between now and then.